So, the current study targets the AKT/mTOR signaling pathway, downstream of ITZ (Head et al., 2015), investigates the anti-cancer effect of monotherapy using ITZ and another drug each, as well as the two in combination, in TNBC cells. The gene discussed is AKT1; the disease is cancer.